orlistat + pioglitazone + lisinopril + diltiazem + atorvastatin

This is a **combination drug** consisting of five distinct agents: - **Orlistat**: a lipase inhibitor used for weight loss, blocking fat absorption in the gastrointestinal tract. - **Pioglitazone**: a thiazolidinedione-class antidiabetic that increases insulin sensitivity. - **Lisinopril**: an angiotensin-converting enzyme (ACE) inhibitor used to manage hypertension and heart failure. - **Diltiazem**: a calcium channel blocker indicated for hypertension and certain cardiac arrhythmias. - **Atorvastatin**: an HMG-CoA reductase inhibitor (statin) used for lowering cholesterol and prevention of cardiovascular disease. No single pharmaceutical product containing all five of these agents together is available or documented in regulatory, clinical, or commercial settings. Instead, each drug is commonly prescribed individually or in dual/triple therapy settings for comorbid metabolic and cardiovascular risk management. The concurrent use of orlistat and pioglitazone, in particular, has been studied and shown to increase the risk of hepatotoxicity, and their combination should be used with caution, especially in patients with liver dysfunction[1][3].